SIRT7: a novel molecular target for personalized cancer treatment?

Oncogene. 2024 Mar;43(14):993-1006. doi: 10.1038/s41388-024-02976-8. Epub 2024 Feb 21.

Abstract

The Sirtuin family of NAD+-dependent enzymes assumes a pivotal role in orchestrating adaptive responses to environmental fluctuations and stress stimuli, operating at both genomic and metabolic levels. Within this family, SIRT7 emerges as a versatile player in tumorigenesis, displaying both pro-tumorigenic and tumor-suppressive functions in a context-dependent manner. While other sirtuins, such as SIRT1 and SIRT6, exhibit a similar dual role in cancer, SIRT7 stands out due to distinctive attributes that sharply distinguish it from other family members. Among these are a unique key role in regulation of nucleolar functions, a close functional relationship with RNA metabolism and processing -exceptional among sirtuins- and a complex multienzymatic nature, which provides a diverse range of molecular targets. This review offers a comprehensive overview of the current understanding of the role of SIRT7 in various malignancies, placing particular emphasis on the intricate molecular mechanisms employed by SIRT7 to either stimulate or counteract tumorigenesis. Additionally, it delves into the unique features of SIRT7, discussing their potential and specific implications in tumor initiation and progression, underscoring the promising avenue of targeting SIRT7 for the development of innovative anti-cancer therapies.

Publication types

  • Review

MeSH terms

  • Carcinogenesis / genetics
  • Cell Transformation, Neoplastic
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Sirtuins* / physiology

Substances

  • Sirtuins
  • SIRT7 protein, human
  • SIRT6 protein, human